Search company, investor...
Search

Founded Year

2010

Stage

Series B | Alive

Total Raised

$14.7M

Last Raised

$8M | 1 yr ago

About Rna Diagnostics

Rna Diagnostics is a molecular diagnostics company developing diagnostic tools to assist in the management of cancer chemotherapy. The company's first product, RNA Disruption Assay (RDA), is a test that helps oncologists to assess the effectiveness of cancer chemotherapy. RDA can determine whether chemotherapy is working effectively in the individual patient early in treatment thereby guiding clinical decision making.

Rna Diagnostics Headquarters Location

21 St. Clair Avenue East, Suite 701 Suite 1204

Toronto, Ontario, M4T 1L9,

Canada

647-221-6909

ESPs containing Rna Diagnostics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market provide tests that help to determine the appropriate course of treatment for a given patient based on their genomic profile. Many solutions in this space also include a software portal that enables physicians to easily navigate the data and make decisions.

Rna Diagnostics named as Outperformer among 13 other companies, including Tempus, Caris Life Sciences, and Genomenon.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Rna Diagnostics's Products & Differentiation

See Rna Diagnostics's products and how their products differentiate from alternatives and competitors

  • RNA Disruption Assay

    The RDA test is performed on core needle biopsies acquired from cancer tumours after administration of chemotherapy drugs. rRNA is isolated from the tumour biopsies and run on a bioanalyzer. The electrophoretic data from the bioanalyzer is analyzed using a proprietary algorithm and RDA scores are produced. Results are reported in 3 zones: nonresponse, partial response, and strong response. Zone 1 (nonresponse) is the actionable information. If an oncologist knows that a patient is not responding to the chemotherapy regimen selected, she/he can stop that regimen, e.g., deliver 2 vs. 4 cycles, and go to another regimen or straight to surgery. The result is de-escalation of treatment based on a patient’s real time response.

    Differentiation

    RDA is performed early during a 5 - 6 month treatment regimen and is highly accurate 

Expert Collections containing Rna Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rna Diagnostics is included in 7 Expert Collections, including Medical Devices.

M

Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,795 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,418 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health IT

7,901 items

Rna Diagnostics Patents

Rna Diagnostics has filed 4 patents.

The 3 most popular patent topics include:

  • Gene expression
  • Genetics
  • MicroRNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/6/2014

8/4/2020

Molecular biology, RNA, Gene expression, Genetics, Cancer treatments

Grant

Application Date

10/6/2014

Grant Date

8/4/2020

Title

Related Topics

Molecular biology, RNA, Gene expression, Genetics, Cancer treatments

Status

Grant

Latest Rna Diagnostics News

Rna Diagnostics Inc Product Pipeline Analysis 2019 Update Published by Global Data Prices from USD $638

Dec 15, 2019

18:34 EST 15 Dec 2019 | BioPortfolio Reports Summary Rna Diagnostics Inc Rna Diagnostics is a medical device company that discovers and develops medical diagnostics molecular diagnostic technologies. The company offers diagnostic tools used in treatment of women undergoing chemotherapy for breast cancer. It also provides solutions to manage cancer and other disease states. Rna Diagnostics' RNA disruption assay allows oncologists to examine the biological structure of a patient's tumor during treatment to determine its response to chemotherapy. The company collaborates with research clinicians, university researchers, and hospitals located in Canada, the US and other countries. It operates through its laboratories located across Ontario, Canada. Rna Diagnostics is headquartered in Toronto, Ontario, Canada. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Rna Diagnostics Inc The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date The report provides detailed description of products in development, technical specification and functions The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio To formulate effective Research Development strategies Develop marketentry and market expansion strategies Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio Note: Some sections may be missing if data is unavailable for the company Related Biotechnology, Pharmaceutical and Healthcare News

  • When was Rna Diagnostics founded?

    Rna Diagnostics was founded in 2010.

  • Where is Rna Diagnostics's headquarters?

    Rna Diagnostics's headquarters is located at 21 St. Clair Avenue East, Suite 701, Toronto.

  • What is Rna Diagnostics's latest funding round?

    Rna Diagnostics's latest funding round is Series B.

  • How much did Rna Diagnostics raise?

    Rna Diagnostics raised a total of $14.7M.

  • Who are the investors of Rna Diagnostics?

    Investors of Rna Diagnostics include iGan Partners, BDC Capital, Medteq, Niagara Angel Network, Golden Triangle Angel Network and 6 more.

  • What products does Rna Diagnostics offer?

    Rna Diagnostics's products include RNA Disruption Assay.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.